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the 5-HT 2A  receptor antagonist KT or the 5-HT 1B/1D  receptor 
antagonist GR125743, respectively.  Results: All UCA seg-
ments showed contractile responses to both 5-HT and su-
matriptan, and the concentration response curves showed a 
rightward shift with increasing concentrations of KT and 
GR125743, respectively, indicating the presence of function-
al 5-HT 2A  and 5-HT 1B/1D  receptors in the foetal tissue. No sig-
nificant differences were found in maximum response (E max ) 
(expressed in percent of response on 100 m M KCl) or poten-
cy (pEC 50 ) of 5-HT in both groups (E max  = 141  8 7.7%, 
pEC 50  = 7.67  8 0.26 in KT-treated group and E max  = 162  8 
12.6%, pEC 50  = 7.69  8 0.14 in non-KT treated group, respec-
tively). No significant differences were found in the potency 
of the antagonist KT in both study groups (pK b  = 7.65  8 0.31 
in KT group and 7.46  8 0.17 in non-KT group, respectively). 
Similarly, with sumatriptan, no significant differences were 
found between KT-treated patients and non-KT treated pa-
tients (E max  =  142  8 16.2 and 140  8 14.7%, respectively, 
pEC 50  = 6.17  8 0.37 and 6.41  8 0.28 respectively, pK b  of 
GR125743 = 7.83  8 0.48 and 8.43  8 0.29, respectively).  Con-
clusion: Foetal exposure to KT in pre-eclamptic patients 
does not seem to influence the functional characteristics of 
5-HT 2A  and 5-HT 1B/1D  receptors in the UCA. 
 Copyright © 2007 S. Karger AG, Basel 
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 Abstract 
 Background: Maternal treatment with the 5-HT 2A  receptor 
antagonist ketanserin (KT) in pre-eclamptic patients is asso-
ciated with a high placental transmission of KT, resulting in 
pharmacologically active levels of KT in the umbilical cord 
artery (UCA) and the neonate. Prolonged exposure to a 5-HT 
receptor antagonist may influence the functionality of foetal 
5-HT receptors and compromise foetal development.  Ob-
jective: To study whether exposure to KT influences the 
characteristics of foetal 5-HT receptors, functional studies 
were performed on 5-HT 2A  and 5-HT 1B/1D  receptors in UCA 
from pre-eclamptic patients treated with KT.  Methods: UCAs 
were obtained, immediately after delivery, from pre-eclamp-
tic patients (n = 7), treated antenatally with intravenous KT. 
Pre-eclamptic patients (n = 13), not treated with KT (non-KT), 
were included as a control group. Segments of UCA were 
prepared and mounted in tissue baths and isometric force 
changes were determined. Cumulative concentration re-
sponse curves to 5-HT and to the 5-HT 1B/1D  receptor agonist 
sumatriptan were constructed in the absence or presence of 
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 Introduction 
 Pre-eclampsia is a disease occurring in 2–5% of the 
pregnant women and it forms one of the leading causes 
of maternal and neonatal mortality and morbidity during 
pregnancy  [1] . The pathophysiology of the disease is not 
yet fully understood, but impaired trophoblast invasion 
and endothelial dysfunction are considered to be impor-
tant factors in the pathogenesis  [1, 2] . The main clinical 
characteristics of pre-eclamptic patients are elevated 
blood pressure, proteinuria and oedema, occurring after 
the twentieth week of gestation. Treatment with antihy-
pertensive drugs is indicated to stabilize the patient and 
prevent maternal complications like organ failure or 
haemorrhages in retina or brain. Preterm delivery of, of-
ten severely growth-restricted, neonates occurs frequent-
ly in early-onset pre-eclamptic patients  [3, 4] .
 In the past years, prolonging the pregnancy of early-
onset pre-eclamptic patients (‘temporizing manage-
ment’), using potent antihypertensive drugs, has been 
undertaken to improve neonatal outcome  [5–7] . One of 
the antihypertensive drugs used most often in the Neth-
erlands in the treatment of pre-eclampsia is the 5-HT 2A  
receptor antagonist ketanserin (KT). The drug is thought 
to act by blocking the vasoconstrictive response to 5-HT 
in the blood vessels, while it is known to have some minor 
   1 -receptor-blocking properties as well  [8] . Its use in pre-
eclampsia is based upon the assumption that an increased 
vasoconstrictive response to 5-HT, leading to increased 
peripheral resistance, is one of the mechanisms involved 
in pre-eclampsia. Hence, the use of a 5-HT antagonist 
such as KT is considered a rational approach in the treat-
ment of pre-eclampsia  [9, 10] . However, for temporizing 
management in severe, early-onset pre-eclamptic pa-
tients, high intravenous dosages of KT are needed for 
prolonged periods of time, resulting in extensive foetal 
exposure to KT. Indeed, concentrations of KT equal to 
maternal levels were found in the umbilical cord (26–373 
ng/ml) and in the neonate (71–302 ng/ml) after maternal 
use of KT  [11] . Whether these pharmacologically active 
concentrations of KT, being a 5-HT 2A  receptor antago-
nist, influence the characteristics and possibly cause de-
sensitization of foetal 5-HT receptors, is unknown. In 
animal studies, chronic blockade of 5-HT 2A  receptors by 
KT has been shown to lead to an unexpected down-regu-
lation of 5-HT 2A  receptors  [12, 13] . 5-HT is known to be 
one of the earliest neurotransmitters produced during 
foetal brain development  [14, 15] . It can be speculated 
that foetal exposure to 5-HT receptor blocking drugs 
such as KT can cause harmful effects on the foetus, espe-
cially considering the abundant presence of 5-HT recep-
tors in the foetal brain. Although the currently available 
human studies have not yet shown clinical adverse effects 
in neonates clearly attributable to maternal KT treatment 
 [8, 11, 16] , studying foetal 5-HT receptors in functional 
studies will yield more detailed information regarding 
foetal development of these receptors and may lead to a 
better assessment of the risk of long-term effects in the 
neonate after maternal KT treatment. In our study, we 
selected the umbilical cord artery (UCA) as representa-
tive of foetal vessels and earlier studies demonstrate that 
5-HT 2A  and 5-HT 1B/1D  are the major receptors mediating 
5-HT-induced vasoconstriction in human UCA  [17] .
 Based on the results of animal studies  [12, 13] , we hy-
pothesized that prolonged exposure of tissue and blood 
vessels to the 5-HT 2A  receptor antagonist KT influences 
the functionality of foetal 5-HT receptors, by down-regu-
lation of the 5-HT 2A  receptor. The functionality of the 
5-HT 1B/D  receptors was also studied, since it was specu-
lated that the inhibiting effect of KT on platelet aggrega-
tion might reduce the release of 5-HT from platelets, 
which in turn may cause alterations in the density of the 
foetal 5-HT 1B/1D  receptor. Moreover, as mentioned earli-
er, beside 5-HT 2A  receptors, 5-HT 1B/1D  is known to be the 
other type of receptors responsible for mediating the 5-
HT vasoconstriction response.
 In the present study, functional responses of 5-HT 2A  
and 5-HT 1B/1D  receptors in UCA from pre-eclamptic pa-
tients treated with KT were compared with responses 
from pre-eclamptic patients not treated with KT.
 Methods 
 Twenty pre-eclamptic patients admitted to the antenatal ward 
of the Erasmus MC were included in the study in the period 2002–
2006. The ethics committee of the Erasmus MC approved the pro-
tocol and all patients gave informed consent prior to inclusion. 
Pre-eclampsia was defined as the occurrence, after 20 weeks of 
gestation, of a diastolic blood pressure  6 110 mm Hg and a pro-
tein/creatinine ratio  6 30 mg/mmol creatinine or the occurrence 
of a repetitive diastolic blood pressure  6 90 mm Hg in combina-
tion with the HELLP (haemolysis, elevated liver enzymes, low 
platelet count) syndrome.
 The patients were divided into 2 study groups; 1 was treated 
with KT before delivery and the other with other antihypertensive 
drugs (dihydralazine, nifedipine or nicardipine) without expo-
sure to KT. All patients in the non-KT group and the majority of 
patients (86%) in the KT group used methyldopa orally.
 KT treatment consisted of an intravenous bolus injection of 10 
mg followed by a continuous infusion of KT at 4 mg/h. According 
to the blood pressure, the infusion rate of KT was increased with 
2 mg/h every 20 min to a maximum of 20 mg/h. Each increment 
 Hanff  /Gupta  /MaassenVanDenBrink  /
Steegers  /Saxena  /Vulto  /Visser  
Neonatology 2007;92:240–247242
was preceded by an intravenous loading bolus injection of 10 mg 
KT. Drug treatment was targeted at an intra-arterial diastolic 
blood pressure of  ^  90 mm Hg. Antihypertensive treatment was 
continued as long as foetal and/or maternal condition did not 
warrant delivery, as judged by the attending obstetrician.
 The umbilical cords were collected immediately after caesar-
ean or vaginal deliveries.
 Umbilical cord was collected in Krebs solution at 4  °  C (compo-
sition in m M : NaCl 118, KCl 4.7, CaCl 2  2.5, MgSO 4  1.2, KH 2 PO 4  
1.2, NaHCO 3  25 and glucose 11.1, pH 7.4), transported to the lab-
oratory and UCA was isolated from the umbilical cord. Function-
al experiments were performed on the same or subsequent day. 
Segments of UCA of 3–4 mm length and 1.5–2 mm internal diam-
eter were suspended with the help of stainless steel hooks in 15-ml 
organ baths filled with carbogenated (95% O 2 , 5% CO 2 ) Krebs so-
lution at 37  °  C. Each segment was set under a tension of 25 mN, as 
determined to be the optimal tension in pilot experiments.
 The segments were washed after every 15 min and were al-
lowed to equilibrate for 45 min, to ensure that no maternal KT 
was present in the vessels before the start of the experiments. Two 
successive challenges to KCl (30 m M , Merck, Darmstadt, Germa-
ny) were performed to check the reproducibility of the response. 
100 m M KCl was subsequently added to determine the reference 
contractile response of the segment. Serotonin (5-HT, Sigma 
Chemicals Co., Steinheim, Germany) and sumatriptan (Pfizer 
Ltd., Sandwich, Kent, UK) were added to different segments in a 
cumulative manner in the absence or presence of antagonists. 
Concentration response curves to 5-HT or to sumatriptan were 
constructed in a parallel set-up in the presence of vehicle or after 
30 min of incubation with the 5-HT 2A  antagonist KT (10 n M , 100 
n M or 1   M ) (Pfizer) or the 5-HT 1B/D  antagonist GR125743 (10 n M , 
100 n M or 1   M , Pfizer)  [18] , respectively. All agonists and an-
tagonists were dissolved in distilled water and stored in aliquots 
at –80  °  C. Only a single concentration response curve was con-
structed in each artery segment.
 Data and Statistical Analysis 
 Clinical characteristics between the 2 groups were compared 
using Wilcoxon’s rank sum test. All contractile responses to the 
agonists were expressed as percentage contraction of the tone in-
duced by 100 m M KCl. All values were expressed as mean  8 SEM. 
The concentration response curves of the agonists were analyzed 
using non-linear regression analysis (Graph Pad Prism 3.01, 
Graph Pad Software Inc., San Diego, Calif., USA). The potency of 
agonist was expressed as pEC 50  [–log(EC 50 )]. The apparent block-
ing potency of the antagonists (apparent pK b ) was estimated by 
calculating concentration ratios between EC 50  values of agonist 
in the presence and in the absence of 100 n M of the antagonists 
KT and GR125743  [19] , assuming a slope of unity.
 Statistical analysis was performed using SPSS (version 11.5, 
SPSS Inc., Chicago, Ill., USA).
 Statistical significance was determined by the Student t test, 
with differences considered significant at p  ! 0.05. A post-hoc 
power analysis was performed to verify whether sufficient pa-
tients were investigated. Correlation coefficients between pEC 50 , 
E max  or pK b  and duration of KT treatment, cumulative dosage or 
maximum dosage was calculated according to Pearson’s coeffi-
cient of correlation (r).
 Results 
 The demographic and clinical characteristics of the 7 
KT-treated and 13 non-KT-treated patients included in 
this study are summarized in  table 1 . The groups did not 
differ significantly with respect to age, gestational age at 
admission or delivery, blood pressure at admission, neo-
natal weight or way of delivery. In all KT-treated patients, 
initially adequate blood pressure control was achieved 
with KT, but in 2 patients alternative intravenous antihy-
pertensive drugs (nicardipine, n = 1; dihydralazine, n = 
1) were added to maintain adequate blood pressure con-
trol. In 1 patient in the KT-treated group, KT treatment 
was stopped 2 h before delivery and in 1 patient 45 h be-
fore delivery. These patients were included in the analysis 
in the KT group because possible effects of maternal KT 
treatment on umbilical cord receptors were assumed to 
persist at least several days, considering the half-life of 5-
HT 2  receptors of 3–5.5 days  [20] and the elimination half-
life of KT of 13–18 h  [21] .
 The response to 100 m M KCl did not differ significant-
ly between the study groups in the KT-treated group (36 
 8 16 mN) versus the non-KT-treated group (24  8 10 
mN). 5-HT and the 5-HT 1B/1D  receptor agonist, sumatrip-
tan, induced potent contractions in the UCA in both 
groups, which did not differ with respect to E max  and pEC 50  
( fig. 1 ,  table 2 ). The concentration response curves to 5-
HT showed a rightward shift after exposure to increasing 
concentrations of the 5-HT 2A  antagonist KT ( table 2 , 
 fig. 2 a, b). In the rightward shifted curves after exposure 
to KT, slightly biphasic shaped curves may be seen ( fig. 2 a, 
b), which can be explained by the affinity of 5-HT to oth-
er 5-HT receptors, which are not antagonized by KT.
 Similarly, 30 min incubation with the 5-HT 1B/1D  an-
tagonist, GR125743, resulted in a rightward shift of the 
concentration response curves to sumatriptan ( table 2 ). 
No statistical differences were found between the pK b  
values for the antagonists (KT or GR125743) of 5-HT re-
ceptors in UCA of pre-eclamptic patients treated with KT 
or those not treated with KT. Although our sample size 
was limited, a post-hoc power analysis (  = 0.05,   = 0.80) 
showed that the group size was sufficiently large to detect 
a difference in pEC 50  of 0.7, corresponding to a 5-fold dif-
ference in potency, which we consider to be clinically rel-
evant.
 Data on duration of KT treatment, cumulative dos-
ages and maximum dosages of the individual patients of 
the KT-treated group are shown in  table 3 . No correla-
tions were found for 5-HT for E max  or pEC 50 , with dura-
tion of KT treatment (for E max , r = –0.539, p = 0.212; for 
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pEC 50 , r = –0.297, p = 0.518), cumulative dosage (for E max , 
r = –0.516, p = 0.236; for pEC 50 , r = –0.379, p = 0.401) and 
maximum dosage, respectively (for E max , r = –0.024, p = 
0.959; for pEC 50  ,  r = –0.333, p = 0.465). Similarly, no cor-
relations were found for sumatriptan for E max  or pEC 50 , 
with duration of KT treatment (for E max , r = 0.021, p = 
0.964; for pEC 50 , r = –0.058, p = 0.902), cumulative dos-
age (for E max , r = 0.105, p = 0.822; for pEC 50 , r = 0.015, 
p = 0.974) and maximum dosage, respectively (for E max , 
r = 0.524, p = 0.227; for pEC 50 , r = –0.272, p = 0.555).
Table 1. Clinical characteristics of pre-eclamptic patients, treated with KT before delivery (n = 7) or treated with 
other drugs (nifedipine, dihydralazine or nicardipine) before delivery (n = 13)
Pre-eclamptic patients
treated with KT
Pre-eclamptic patients not
treated with KT
Age, years 34 [25–41] 31 [18–44]
BP diastolic at admission, mm Hg 105 [851–120] 100 [90–120]
BP systolic at admission, mm Hg 180 [140–220] 160 [110–200]
Protein/creatinine ratio, mg/mmol 325 [80–1,856] 470 [127–1,257]
Gestational age at admission, weeks 28 [25 4/7–35] 29 4/7 [24 4/7–34 6/7]
Gestational age at delivery, weeks 31 [26 4/7–36 2/7] 30 6/7 [26 3/7–36 6/7]
Way of delivery
Caesarian 7 (100) 12 (92)
Vaginal 0 1 (8)
Twin gestation 0 1 (8)
KT use
Duration of treatment, h 54 [17–399] –
Maximum dosage, mg/h 9 [6–18] –
Cumulative dosage, mg 379 [160–3,055] –
Other antihypertensive drugs
Methyldopa p.o. 6 (86) 9/9.13 (100)
Median dosage at delivery, g 3 [2–4] 3.5 [1.5–4]
Nifedipine p.o. 2 (29) /000.5 (38)
Dihydralazin i.v. 1 (14) 3 (23)
Nicardipin i.v. 4 (57) 3 (23)
Neonatal weight, g 1,035 [750–1,985] /1,205 [650–2,165]
Below 10th percentile 2 (28) 6 (46)
Below 2.3th percentile 1 (14) 1 (8)
Data are expressed as medians (with ranges in square brackets) or numbers (with percentages in parenthe-
ses).
1 One patient with severe HELLP syndrome.
Table 2. 5-HT receptor characteristics, expressed as mean (8 SEM) of Emax, pEC50 and pKb from UCA obtained 
from pre-eclamptic patients treated with KT and from pre-eclamptic patients not treated with KT
Pre-eclamptic patients treated with KT Pre-eclamptic patients not treated with KT
5-HT sumatriptan 5-HT sumatriptan
Emax 14187.7 (n = 7) 142816.2 (n = 7) 162812.6 (n = 11) 140814.7 (n = 11)
pEC50 7.6780.26 (n = 7) 6.1780.37 (n = 7) 7.6980.14 (n = 11) 6.4180.28 (n = 11)
pKb 7.6580.31 (n = 5) 7.8380.48 (n = 4) 7.4680.17 (n = 10) 8.4380.29 (n = 8)
5-HT and sumatriptan were used as agonists in the absence or presence of KT (100 nM) and GR125743 
(100 nM) as their respective antagonists. Emax: expressed as percentage of the response induced by 100 mM 
KCl.
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Table 3. Individual 5-HT receptor characteristics, expressed as Emax and pEC50 from UCA obtained from pre-
eclamptic patients treated with different dosages of KT
Patient Duration of
KT treatment
h
Cumulative
dosage of KT
mg
Maximum
dosage of KT
mg/h
5-HT Sumatriptan
Emax pEC50 Emax pEC50
1 27 338 14 196 7.63 223 5.40
2 110 379 9 142 8.74 111 5.42
3 399 3,055 18 99 7.21 145 6.53
4 121 850 10 164 6.63 173 5.12
5 17 160 8 128 7.62 102 7.32
6 54 414 8 127 8.24 115 5.80
7 28 174 6 130 7.6 130 7.60
5-HT and sumatriptan were used as agonists. Emax: expressed as percentage of the response induced by 100 
mM KCl.
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 Fig. 1. Concentration response curves to 5-HT in UCA segments 
of KT-treated patients ( U , n = 7) and of patients not treated with 
KT ( S , n = 13) and concentration response curves to sumatriptan 
in UCA segments of KT-treated patients ( $ , n = 7) and of patients 
not treated with KT ( ) , n = 13). 
 Fig. 2. Concentration response curves to 5-HT in the absence ( U ) 
or presence of increasing concentrations of the 5-HT 2A  receptor 
antagonist, KT [10 n M ( o ), 100 n M ( $ ) and 1   M ( X )], in UCA 
segments of KT-treated patients (n = 7;  a ) and of patients not treat-
ed with KT (n = 13;  b ). 
1
 2 
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 Discussion 
 The presence of 5-HT 2A  and 5-HT 1B/1D  receptors in 
utero-placental vessels of normotensive patients has been 
described by several authors  [22–24] . Increased concen-
trations of 5-HT have been reported at birth in maternal 
and placental circulation  [25] , indicating a role for 5-HT 
in maintaining vascular tone at birth. In pre-eclampsia, 
Middelkoop et al.  [26] showed an increase in maternal 
circulation of 5-HT in pre-eclamptic patients, suggesting 
a role for 5-HT in the aetiology of pre-eclampsia.
 In agreement with these studies, we found that 5-HT 
and sumatriptan induced contractions in all UCA tested, 
indicating the presence of 5-HT receptors. KT and 
GR125743 shifted the 5-HT and sumatriptan curves 
rightwards in a concentration-dependent manner, con-
firming the presence of functional 5-HT 2A  and 5-HT 1B/1D  
receptors in UCA. The pK b  values (7.65 and 7.46) of KT 
against 5-HT are 1 log unit lower than the pA 2  values of 
8.7–8.9 described by other authors for UCA  [17, 27] . This 
might be explained by the fact that the blocking activity 
of KT is being underestimated in our experiments be-
cause 5-HT will have functional affinity for the 5-HT 1  
receptor or other 5-HT subtypes  [28] as well. Even though 
5-HT is not a selective 5-HT 2A  receptor agonist, we chose 
5-HT as an agonist in this study as it encompasses the 
study of all 5-HT receptor subtypes and allows compari-
son of our results with other studies on 5-HT receptor 
functionality  [17, 29, 30] . Furthermore, our results are in 
line with previously reported values of pA 2  of 7.7–7.85 for 
5-HT 2A  receptor in animal tissue  [31, 32] .
 The pK b  value of GR125743 (7.83–8.43) for sumatrip-
tan is in accordance with previously observed pA 2  values 
of 8.18 in human coronary artery and 8.34 in human sa-
phenous vein  [33] .
 The 5-HT 2A  receptor antagonist KT has been increas-
ingly used as an antihypertensive drug in pre-eclamptic 
patients in recent years. However, the substantial trans-
placental transmission and subsequently high foetal ex-
posure to KT  [11] may lead to adverse effects on foetal 
5-HT receptors. The early appearance and continued ex-
pression of foetal 5-HT receptors during gestation has 
been demonstrated in animal studies  [15] . Lauder et al. 
 [15] showed in mouse embryos that both structural as 
well as functional damage occurred after foetal exposure 
to high dosages of the 5-HT 2A/2C  receptor antagonist, mi-
anserin, and the 5-HT 2A/2B/2C  receptor antagonist, ritan-
serin. No malformations were found after foetal exposure 
to KT. Whitaker et al.  [34] demonstrated in animal stud-
ies that foetal exposure to the 5-HT receptor agonist, 5-
methoxytryptamine, or exposure to a decreased level of 
maternal 5-HT (achieved by adding a tryptophan hy-
droxylase inhibitor antagonist) resulted in down-regula-
tion and up-regulation of 5-HT receptors in newborn off-
spring, respectively.
 In humans, only data on foetal effects after use of se-
lective serotonin re-uptake inhibitors during pregnancy 
are available. These drugs have shown to affect foetal 5-
HT regulation, resulting in adverse effects on neonatal 
behaviour (tremor, restlessness, rigidity postnatally) fol-
lowing gestational exposure  [35, 36] . Based on the afore-
mentioned data on adverse foetal effects after maternal 
drug use, we studied the effect of maternal KT treatment 
on foetal 5-HT receptor functional characteristics in pre-
eclamptic patients. We hypothesized, based on animal 
studies  [12, 13] , that foetal exposure to KT might influ-
ence the functionality of 5-HT 2A  receptor and eventually 
also the 5-HT 1B/1D  receptor.
 Our data show no significant differences in 5-HT- or 
sumatriptan-induced vasoconstrictive responses of the 
UCA between the pre-eclamptic group treated with KT 
and the pre-eclamptic group without exposure to KT, in-
dicating that exposure to KT does not influence foetal 
5-HT 2A  and 5-HT 1B/1D  receptor characteristics in UCA.
 Dosage and Duration of Treatment 
 It can be expected that high dosages of KT and long-
term treatment will exert a more pronounced effect on 
receptor characteristics than lower dosages, although all 
dosages used in this study were in the pharmacologically 
active range and have been known to cause high umbili-
cal cord plasma levels of KT  [11] . These plasma levels are 
in the same range as the concentrations of KT used in our 
in vitro experiments, indicating that results obtained 
with our experiments are of clinical relevance.
 In our study no relationship between dosage and pEC 50 , 
E max  or pK b  could be established. It should be borne in 
mind that the number of patients in our study was rela-
tively small, due to the fact that many early-onset pre-
eclamptic patients need alternative treatment before de-
livery after the maximum dosage of KT is reached. How-
ever, power analysis established that the statistical power 
in our study was sufficient to detect a 5-fold difference in 
potency, which we consider clinically relevant.
 Gestational Age 
 Limited information is available with respect to the 
influence of gestational age on the response of the um-
bilical artery to 5-HT. Bertrand and St-Louis  [29] showed 
an increase in umbilical and placental vein sensitivity to 
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serotonin throughout the third trimester in normoten-
sive patients, whereas this change was not seen in pre-
 eclampsia. We also showed that with advancing gesta-
tional age, an increase in the sensitivity of 5-HT 1B/1D  re-
ceptors in UCA in normotensive patients can be found 
 [37] . In our study the groups did not differ with respect 
to gestational age, therefore a possible confounding factor 
of gestational age on the results was excluded. However, 
it can be speculated that clinical effects of maternal KT 
treatment on the receptor population will (partly) depend 
on gestational age, if sensitivity to 5-HT in UCA indeed 
changes with gestational age.
 Our results, suggesting a lack of effect of maternal KT 
treatment on the functionality of 5-HT receptors in UCA, 
support the currently available clinical data, showing that 
use of KT in pre-eclamptic patients is safe for foetus and 
neonate.
 In conclusion, prolonged foetal exposure to KT in pre-
eclamptic patients does not seem to influence the func-
tional characteristics of 5-HT 2A  and 5-HT 1B/1D  receptors 
in the UCA.
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